LLY
758.12
+2.89%↑
JNJ
151.16
+1.45%↑
UNH
291.21
+7.79%↑
ABBV
182.59
+1.45%↑
NVO
64.13
-2.91%↓
LLY
758.12
+2.89%↑
JNJ
151.16
+1.45%↑
UNH
291.21
+7.79%↑
ABBV
182.59
+1.45%↑
NVO
64.13
-2.91%↓
LLY
758.12
+2.89%↑
JNJ
151.16
+1.45%↑
UNH
291.21
+7.79%↑
ABBV
182.59
+1.45%↑
NVO
64.13
-2.91%↓
LLY
758.12
+2.89%↑
JNJ
151.16
+1.45%↑
UNH
291.21
+7.79%↑
ABBV
182.59
+1.45%↑
NVO
64.13
-2.91%↓
LLY
758.12
+2.89%↑
JNJ
151.16
+1.45%↑
UNH
291.21
+7.79%↑
ABBV
182.59
+1.45%↑
NVO
64.13
-2.91%↓
24h
Current
Min
7.47
Max
7.98
Income | -41M -65M |
---|---|
Profit margin | -82.56 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +90.54% upside |
Next Earnings | 6 Aug 2025 |
---|
Past performance is not a reliable indicator of future results.
8 May 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 Dec 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15.11 USD 90.54%
High 20 USD
Low 10 USD
Based on 9 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
9 ratings
9
Buy
0
Hold
0
Sell
Based on 9 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$